The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study
Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
Authors: G. E. Umpierrez, T. Blevins, J. Rosenstock, C. Cheng, J. H. Anderson, E. J. Bastyr, for the EGO Study Group
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: glucagon-like peptide-1 analogues, GLP-1 receptor agonists, type 2 diabetes, overweight and obesity, glycated haemoglobin A1c, blood glucose, weight loss, dose escalation, adverse events, hypoglycemia, gastrointestinal adverse effects, insulin-independent glucose lowering, subcutaneous injection
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W2108106161
